Class Action Article

  • File A Talcum Powder Lawsuit: Talcum Powder Ovarian Cancer Lawsuits Talcum Powder Fallopian Tube Cancer Lawsuits Baby  Powder Ovarian Cancer Lawsuits Filed If you or a loved one used talcum powder products and were diagnosed with ovarian cancer, or fallopian tube can...

Class Action News

Drug Class Actions

  • Taxotere Lawyers for Permanent Hair Loss: Taxotere Baldness Lawyers For  Permanent Hair Loss Lawsuits Have you received Taxotere for breast cancer? Taxotere can result in hair loss or baldness  that is permanent. Taxotere  is a chemotherapy drug used for the treatment of breas...

Medical Device Lawsuits

  • Zimmer Hip Replacement Lawyers: Network Zimmer Hip Replacement  Lawyer Win $2 Million Against Zimmer Hip Replacement Do You Have A Faulty Zimmer M/L Taper Hip Prothesis With Connective Technology and Cobalt Chromium Head? Do You Have Have Metallosis or Chromium Cobalt T...

Posts Tagged ‘west palm beac’

Actos Lawyers Filing Actos Lawsuits, Actos Linked to Bladder Cancer

Written by Class Action Lawyer on . Posted in Actos Lawsuit Lawyers, Drug Lawsuits, Multidistrict Lawsuit News

Actos Linked To Bladder Cancer

 Actos has been linked to bladder cancer with use of over 2 years.

Seniors and minority groups are usual victims of Actos. Actos is a drug used for Type II, adult onset, diabetis.

Thousands of Actos Bladder Cancer  Lawsuits Are  Anticipated

Actos Timeline Gives The Actos Lawsuit Statute  Starting Date

Jun 10, 2011: Use of Actos is banned in France and Germany. The French Medicines Agency removed the drug from the market after analyzing the data collected from 2006 to 2009.

Jun. 15, 2011: FDA announces “that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer.” Warning labels are to be updated subsequently. The agency warns healthcare professionals against prescribing Actos in patients who have bladder cancer or have a history of bladder cancer.

Jul. 2011: The EMA states that Actos should include the risk of bladder cancer on its warning label, according to Reuters.

Aug.  4, 2011: – The FDA approves the label change for product containing pioglitazone (marketed as Actos, Actoplus Met, and Duetact) previously announced on June 15, 2011.

Actos Lawsuit  MDL Consolidation

Actos pillsThousands of Actos lawsuits are anticipated in the multidistrict litigation (MDL) filing ordered by Judge Rebecca Doherty. The honorable Judge Doherty stated in a recent order that "the number of claims which will be included could reach into the thousands," in reference to the new Actos lawsuit MDL she ordered be created. Judge Doherty is not presiding over an Actos class action lawsuit.
The MDL was created so that Judge Doherty will have one common point of reference for the thousands of cases expected. This specific MDL lets all of the affected Actos users work together so they are all essentially covered under one lawsuit (similar to a class action.) Unlike an Actos class action lawsuit, where the payout per participant may be small, an award from the Actos MDL could amount to tens or hundreds of thousands of dollars per litigant. It could even be in the million dollar range if the an Actos user's death was tied back to taking Actos and developing bladder cancer or another severe adverse side effect of Actos.

Get An Actos Lawyer

An experienced Actos attorney will be able to help determine what financial awards may be possible based on the severity of the injury and required treatment due to taking Actos.

Actos Bladder Cancer Symptoms

It's important that Actos users know what to look out for if they have taken Actos for more than one year which allegedly increases the risk of bladder cancer by at least 40%. Symptoms of bladder cancer include tumors which could cause blood in the urine, painful or frequent urination, or straining during urination. In addition, other common symptoms of bladder cancer include fatigue, incontinence, weight loss and bone pain or tenderness. If you are experiencing these symptoms you should see a doctor immediately so bladder cancer or tumors can be ruled out.

Speak To An Actos Bladder Cancer Lawyer and See Your Doctor Right Away

If you are experiencing these symptoms and are diagnosed with bladder cancer or tumors it may be a good idea to speak with an attorney to see if you are able to file an Actos lawsuit under the new MDL.

 

Bard Begins Trials for Vaginal Mesh, Vaginal Mesh Lawyers Ready

Written by Class Action Lawyer on . Posted in Medical Device Lawsuits, Transvaginal mesh

Bard Faces First Federal Trial Over Vaginal Mesh Next Year

C.R. Bard Inc. will face its first federal-court trial next year over claims that the company’s vaginal-mesh implants injured women.

U.S. District Judge Joseph R. Goodwin in Charleston, West Virginia, set a Feb. 5 trial date for the first of about 600 federal cases contending that Bard’s Avaulta device caused organ damage. Goodwin is overseeing a consolidation of cases filed in federal courts across the U.S. against Bard, Johnson & Johnson and other makers of vaginal-mesh inserts.

The order of trials for the first federal cases over Avaulta “will be determined after completion” of pretrial information exchanges between Bard and the plaintiffs, Goodwin said in his order yesterday.

Bard, based in Murray Hill, New Jersey, and a unit of New Brunswick, New Jersey-based J&J also face litigation in U.S. state courts over their mesh products. More than 75,000 women a year have the devices inserted vaginally to treat pelvic organs that bulge, or prolapse, or to deal with incontinence.

Scott Lowry, a Bard spokesman, didn’t immediately return a call for comment on the judge’s decision to set the trial date.

A U.S. Food and Drug Administration report in August 2011 found that vaginal-mesh products should be classified as posing a high risk to patients based on a review of side-effect reports submitted to regulators from January 2008 to December 2010. Women’s groups are demanding that the devices be recalled.

More Study

In January, the FDA ordered 31 manufacturers, including Bard and J&J (JNJ) (JNJ), to study rates of organ damage and complications linked to the vaginal-mesh implants. The companies must conduct three years of studies on the devices’ safety and effectiveness, regulators said. Some women contend the devices eroded and shrank over time, causing pain and injuries.

Some mesh suits blaming Bard and J&J for injuries are pending in state court in Atlantic City, New Jersey. Superior Court Judge Carol Higbee is coordinating discovery in those cases. Higbee has set a Nov. 5 trial for the first case against J&J’s Ethicon unit over claims that its Gynecare Prolift vaginal-mesh insert harmed women.

In February, the Judicial Panel on Multidistrict Litigation consolidated federal suits against pelvic mesh makers before Goodwin. The judge is overseeing evidence-gathering efforts in cases against Bard, J&J, Boston Scientific Corp. (BSX) (BSX) and the American Medical Systems unit of Endo Pharmaceutical Holdings Inc.

Endo’s AMS unit also faces claims in state courts in Delaware and Minnesota over its Perigee, Apogee and Elevate surgical mesh products, according to court filings.

‘Day In Court’

Goodwin has appointed Bryan Aylstock, Fred Thompson III and Henry G. Garrard III to lead a group of plaintiffs’ lawyers who will oversee the progress pretrial information exchanges over the consolidated federal cases.

Aylstock, a Pensacola, Florida-based lawyer, said he was pleased Goodwin set the first trial over Bard’s mesh product for early next year.

“We have a lot of women who have suffered devastating consequences from the Avaulta product and they deserve their day in court,” the plaintiffs’ lawyer said in a telephone interview.

The Bard consolidated cases are In re C.R. Bard Inc. Pelvic Repair System Products Liability Litigation, 2:10-MD-02187, U.S. District Court, Southern District of West Virginia (Charleston).

To contact the reporters on this story: Jef Feeley in Wilmington, Delaware, at jfeeley@bloomberg.net; David Voreacos in Newark, New Jersey, at dvoreacos@bloomberg.net

Multi District Litigation Vaginal Mesh  lawyers are ready to file.

Trials for failed DePuy Hip Replacements Ready to Begin, DePuy lawyers Accepting Cases Now

Written by Class Action Lawyer on . Posted in Arizona Multidistrict Litigation Lawyers, California Multidistrict Litigation Lawyers, Colorado Multidistrict Litigation Lawyers, Connecticut Multidistrict Litigation Lawyers, Florida Multidistrict Litigation Lawyers, Georgia Multidistrict Litigation Lawyers, Indiana Multidistrict Litigation Lawyers, Iowa Multidistrict Litigation Lawyers, Kansas Multidistrict Litigation Lawyers, Maryland Multidistrict Litigation Lawyers, Massachusetts Multidistrict Litigation Lawyers, Michigan Multidistrict Litigation Lawyers, Nevada Multidistrict Litigation Lawyers, New Jersey Multidistrict Litigation Lawyers, New Mexico Multidistrict Litigation Lawyers, New York Multidistrict Litigation Lawyers, North Carolina Multidistrict Litigation Lawyers

DePuy Hip Recall trials ready to begin. DePuy Hip Replacement Lawyers accepting cases in many states. If , need revision surgery or have had revision surgery or metal on  metal toxicity we want to speak to you right away. Only claim in state with 2 year statutes or greater are being accepted. Call right away as time is running out. If you have complications from your dePuy hip replacement see a doctor immediately
The first bellwether trials in the pending DePuy hip litigation are scheduled to begin later this year. The handful of plaintiffs involved in the trials represent just a few of the thousands of individuals who filed suit against Johnson & Johnson and DePuy Orthopedics after being injured by a defective metal hip implant. mny of these have been seniors needing revision surgeries.

According to a Bloomberg report, the first bellwether case is scheduled to go to trial in a Nevada court in December of this year. Additional bellwether trials are expected to begin in January 2013. According to the report, these cases are part of an estimated 2,000 DePuy hip lawsuits filed in state courts across the country. Several thousand more lawsuits are also pending in federal court after being consolidated into a multidistrict litigation (MDL) for pretrial proceedings. The plaintiffs involved in the DePuy hip litigation allege that they experienced pain, swelling, tissue damage, loss of mobility and other complications after being fitted with an ASR all-metal hip implant.  The lawsuits also allege that DePuy and Johnson & Johnson knew of potential problems with the metal hip replacement devices but did not take adequate steps to warn consumers of the dangers.

DePuy Orthopaedics issued a global recall of the ASR Hip Resurfacing System and ASR Acetabular System in August 2010, after data from the National Joint Registry of England and Wales showed that 1 out of every 8 patients (12%-13%) who had received the devices had to undergo revision surgery within five years of receiving it. According to Parker Waichman LLP, more than 93,000 metal-on-metal DePuy ASR hip implants were sold worldwide prior to their recall.

The U.S. Food & Drug Administration (FDA) is currently conducting a safety review of metal-on-metal hip implants, including the DePuy ASR devices. Last May, the agency directed 21 companies that market all-metal hip replacements, including DePuy, to conduct post-market studies of their products to determine if they were shedding dangerous amounts of metallic debris in patients. The FDA recently announced that its Orthopaedic and Rehabilitation Devices Panel will meet on June 27 and 28 to discuss the risks and benefits of metal-on-metal hip systems, and make potential patient and practitioner recommendations for their use.

It is strongly urged that anyone who has a failed DePuy see their Doctor immediately to find out if revision surgery is recommended and speak to a DePuy Lawyer right away

 

 

Birth Control Pills Label Change, Risk of Blood Clots, Birth Contol Pills Lawyers

Written by Class Action Lawyer on . Posted in Class MDL Class Action News

Birth Control Pills Containing Drospirenone: Label Change-Products may be associated with a higher risk for blood clots. Injury lawyers accepting cases for blood clots from yaz or Yasmin. Yaz is just another one of the dangerous drugs and medical devices harming women like the vaginal mesh and Mirena IUD. If you have been injured by Yaz, yasmin, the Mirena IUD, The Vaginal Mesh or any other you must take action and contact a lawyer immediately. Different states have different statutes of limitations, Do Not wait. Time is not on your side. You must get medical attention. Your lawyer will need a statement from a treating physician that says you were injured and it is related to one of these.
April 10, 2012

Yasmin Side Effects, Yaz side effects include bood clots. Speak to a Yaz, Yasmin lawyer today.
 

Audience: OBGYN, Family Practice, Patient

ISSUE: FDA has completed its review of recent observational (epidemiologic) studies regarding the risk of blood clots in women taking drospirenone-containing birth control pills.Based on this review, FDA has concluded that drospirenone-containing birth control pills may be associated with a higher risk for blood clots than other progestin-containing pills.

BACKGROUND:  Drospirenone is a synthetic version of the female hormone, progesterone, also referred to as a progestin. FDA is adding information about the studies to the labels of drospirenone-containing birth control pills.

The revised drug labels will report that some epidemiologic studies reported as high as a three-fold increase in the risk of blood clots for drospirenone-containing products when compared to products containing levonorgestrel or some other progestins, whereas other epidemiological studies found no additional risk of blood clots with drospirenone-containing products.  The labels also will include a summary of the previously released results of an FDA-funded study of the blood clot risk.

RECOMMENDATION: Women should talk to their healthcare professional about their risk for blood clots before deciding which birth control method to use.

Healthcare professionals should consider the risks and benefits of drospirenone-containing birth control pills and a woman’s risk for developing a blood clot before prescribing these drugs.

Healthcare professionals and patients are encouraged to report adverse events or side effects related to the use of these products to the FDA's MedWatch Safety Information and Adverse Event Reporting Program. If you or a loved on as a blood clot injury or deathe due to Yaz or Yasmin Birth control piils call our Yaz, yasmin team today.

New Breast Implants Approved by the FDA, Breast Implant Lawyers

Written by Class Action Lawyer on . Posted in Class MDL Class Action News

New Silicone Gel-filled Breast Implant Approved with Conditions
Saturday, March 10, 2012 :: Staff infoZine
Long-term safety and effectiveness outcomes as well as the risks of rare disease outcomes, still to be studied.

Washington, D.C. – infoZine – The U.S. Food and Drug Administration approved a silicone gel-filled breast implant manufactured by Sientra Inc. to increase breast size (augmentation) in women at least 22 years old and to rebuild breast tissue (reconstruction) in women of any age.

As a condition of approval, Sientra is required to conduct post-approval studies that will assess long-term safety and effectiveness outcomes as well as the risks of rare disease outcomes.

Silicone gel-filled breast implants are medical devices implanted under the breast tissue or under the chest muscle for breast augmentation or reconstruction. These implants have a silicone outer shell that is filled with silicone gel. They come in different sizes and have either smooth or textured shells.

Breast reconstruction includes primary reconstruction to replace breast tissue that has been removed due to cancer or trauma or that has failed to develop properly due to a severe breast abnormality. Breast reconstruction also includes revision surgery to correct or improve the result of a primary breast reconstruction surgery.

Breast augmentation includes primary breast augmentation to increase the breast size, as well as revision surgery to correct or improve the result of a primary breast augmentation surgery.

With today's approval, there are now three FDA-approved silicone gel-filled breast implants in the U.S. manufactured by Allergan, Mentor and Sientra.

"Data on these and other approved silicone gel-filled breast implants continue to demonstrate a reasonable assurance of safety and effectiveness," said William Maisel, M.D., M.P.H., deputy director for science in the FDA's Center for Devices and Radiological Health.

"It's important to remember that breast implants are not lifetime devices. Women should fully understand risks associated with breast implants before considering augmentation or reconstruction surgery, and recognize that long-term monitoring is essential." said Maisel.

The FDA based its Sientra approval on three years of clinical data from 1,788 participants. Complications and outcomes reflected those found in previous studies of other breast implants and included tightening of the area around the implant (capsular contracture), re-operation, implant removal, an uneven appearance (asymmetry), and infection.

Breast Implant lawyers are currently helping women who have filed claims with deficiency notices and proof of disease and manufacturer. Many women were harmed by silicone breat implant toxicity from the silicone in the Implant.

In June 2011, the FDA released a report that included preliminary safety data from post-approval studies from earlier breast implant approvals. The experience collecting and analyzing data from these studies informed the design and structure of post-approval studies for Sientra breast implants.

In addition to other post-approval conditions, Sientra will:

    continue to follow the 1,788 clinical trial participants in their pre-market study for an additional 7 years;
    conduct a 10-year study of 4,782 women receiving Sientra silicone gel-filled breast implants to collect information on long-term local complications such as capsular contracture, as well as less common disease outcomes, such as rheumatoid arthritis and breast and lung cancer; and
    conduct five case-control studies that will evaluate the association between Sientra's silicone gel-filled breast implants and five rare diseases: rare connective tissue disease, neurological disease, brain cancer, cervical/vulvar cancer, and lymphoma.

"The design of these post-approval studies will require Sientra to collect valuable safety information with adequate enrollment and follow-up," said Maisel. "The FDA is committed to working with breast implant manufacturers to collect useful post-market data on long-term safety and effectiveness."

This is all well and good but, what about the thousands of women with diseases and prior breast implant claims. Many of these women are suffering with silicone toxicity related diseases from ruptured and leaking breast implants. Class action lawyers are still helpling women with prior breasrt implant claims.

Tylenol and Liver damage causes deaths, Tylenol Lawyers

Written by Class Action Lawyer on . Posted in Class MDL Class Action News

Liver Failure and Warnings for Acetaminophen most common Cause of acute Liver failure resulting in Death in the United States

Class action Tylenol lawyers accepting client for liver damage from Tylenol overdose. If your loved one has liver failure from Tylenol or you have lost a loved on speak to one of our Tylenol wrongful death lawyers today

(alcohol – liver failure and warnings for acetaminophen and NSAIDS) "… we [the U.S. Food and Drug Administration, HHS] have recent data suggesting that acetaminophen may be the most common cause of acute liver failure in the United States (Ref. 13). Therefore,we believe that the word “severe” is appropriate in the liver warning. In addition, we agree with the submission that the word “severe” is also appropriate in the stomach bleeding warning on OTC NSAID [nonsteroidal anti-inflammatory drug] products."

Editor's Note: The required labeling for acetaminophen and NSAID products in this Federal Register entry was:

"For products containing acetaminophen:
"Alcohol Warning: If you consume 3 or more alcoholic drinks every day, ask a doctor whether you should take acetaminophen or other pain relievers/fever reducers. Acetaminophen may cause liver damage."

"For products containing NSAIDs:
"Alcohol Warning: If you consume 3 or more alcoholic drinks every day, ask your doctor whether you should take (name of active ingredient) or other pain relievers/fever reducers. (Name of active ingredient) may cause stomach bleeding."

Source: 

Food and Drug Administration, HHS, "Organ-Specific Warnings; Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use; Final Monograph," Federal Register, Vol. 74, No. 81, Wednesday, April 29, 2009, p. 19391.
Tylenol lawyers accepting clients with liver complications from Tylenol.

Tylenol lawyers accepting liver failure cases resulting in wrongful death